Research ArticleClinical Investigations
Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry
Bruce E. Hillner, Barry A. Siegel, Lucy Hanna, Fenghai Duan, Anthony F. Shields and R. Edward Coleman
Journal of Nuclear Medicine April 2014, 55 (4) 574-581; DOI: https://doi.org/10.2967/jnumed.113.130005
Bruce E. Hillner
1Department of Internal Medicine and the Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
Barry A. Siegel
2Division of Nuclear Medicine, Mallinckrodt Institute of Radiology and the Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri
Lucy Hanna
3Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, Rhode Island
Fenghai Duan
3Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, Rhode Island
Anthony F. Shields
4Karmanos Cancer Institute, Wayne State University, Detroit, Michigan; and
R. Edward Coleman
5Department of Radiology, Duke University School of Medicine, Durham, North Carolina

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 55, Issue 4
April 1, 2014
Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry
Bruce E. Hillner, Barry A. Siegel, Lucy Hanna, Fenghai Duan, Anthony F. Shields, R. Edward Coleman
Journal of Nuclear Medicine Apr 2014, 55 (4) 574-581; DOI: 10.2967/jnumed.113.130005
Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry
Bruce E. Hillner, Barry A. Siegel, Lucy Hanna, Fenghai Duan, Anthony F. Shields, R. Edward Coleman
Journal of Nuclear Medicine Apr 2014, 55 (4) 574-581; DOI: 10.2967/jnumed.113.130005
Jump to section
Related Articles
Cited By...
- 18F-NaF PET/CT of Obese Patients on a Lutetium-Yttrium Oxyorthosilicate PET/CT System: Patient Dosimetry, Optimization of Injected Activity, and Acquisition Time
- Molecular Imaging of Bone Metastases and Their Response to Therapy
- 18F-Sodium Fluoride PET: History, Technical Feasibility, Mechanism of Action, Normal Biodistribution, and Diagnostic Performance in Bone Metastasis Detection Compared with Other Imaging Modalities
- Observer Agreement and Accuracy of 18F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer
- No Added Value of 18F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy
- Intended Versus Inferred Treatment After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry
- The Injustice of Being Judged by the Errors of Others: The Tragic Tale of the Battle for PET Reimbursement
- Anatomic and Molecular Imaging in Prostate Cancer
- Hospice Admission and Survival After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry
- Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer
- 18F-Fluoride PET in the Assessment of Malignant Bone Disease
- Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT
- Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival
- 18F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry
- Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry
- PET/CT with Sodium 18F-Fluoride for Management of Patients with Prostate Cancer